Relapsed/Refractory Peripheral T-cell Lymphoma
Showing 1 - 25 of >10,000
Relapsed/Refractory Peripheral T-cell Lymphoma Trial in Fairport (Tolinapant, Decitabine + Cedazuridine)
Recruiting
- Relapsed/Refractory Peripheral T-cell Lymphoma
- Tolinapant
- Decitabine + Cedazuridine
-
Aurora, Colorado
- +2 more
Jan 3, 2023
T-cell Lymphoma Patients After First-line Treatment Failure Trial (SHR2554; Chidamide analog tablets, SHR2554 analog tablets;
Not yet recruiting
- T-cell Lymphoma Patients After First-line Treatment Failure
- SHR2554; Chidamide analog tablets
- SHR2554 analog tablets; Chidamide
- (no location specified)
Nov 5, 2023
Peripheral T Cell Lymphoma Trial in Shanghai (Azacitidine Injection, Dasatinib, Linperlisib)
Recruiting
- Peripheral T Cell Lymphoma
- Azacitidine Injection
- +6 more
-
Shanghai, Shanghai, ChinaRuijin Hospital, Shanghai Jiao Tong University School of Medicin
Nov 8, 2022
Peripheral T Cell Lymphoma, Relapsed Peripheral T-Cell Lymphoma, Refractory T-Cell Lymphoma Trial in Xiamen (Chidamide combined
Recruiting
- Peripheral T Cell Lymphoma
- +2 more
- Chidamide combined with Duvillisib
-
Xiamen, Fujian, ChinaThe First Affiliated Hosptial of Xiamen University
Nov 28, 2023
Relapsed/Refractory Peripheral T-cell Lymphoma Trial in Suzhou (Anti-PD-1 mAb, Lenalidomide, Azacitidine)
Recruiting
- Relapsed/Refractory Peripheral T-cell Lymphoma
- Anti-PD-1 monoclonal antibody
- +2 more
-
Suzhou, Jiangsu, ChinaThe First Affiliated Hospital of Soochow University
Dec 21, 2021
Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) Trial (GFH009)
Not yet recruiting
- Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
- (no location specified)
Jun 28, 2023
Folliculotropic Mycosis Fungoides, Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent Mycosis Fungoides Trial in United
Recruiting
- Folliculotropic Mycosis Fungoides
- +7 more
- Durvalumab
- +2 more
-
Duarte, California
- +3 more
Jan 12, 2023
Treatment, Peripheral T-cell Lymphoma Trial in Beijing (liposomal mitoxantrone HCl, gemcitabine, dexamethasone, and cisplatin)
Recruiting
- Treatment
- Peripheral T-cell Lymphoma
- liposomal mitoxantrone hydrochloride, gemcitabine, dexamethasone, and cisplatin
-
Beijing, China
- +4 more
Jun 28, 2022
Peripheral T Cell Lymphoma Trial in Zhengzhou (SHR0302)
Not yet recruiting
- Peripheral T Cell Lymphoma
-
Zhengzhou, Henan, ChinaHenan cancer hospital
Jun 2, 2023
Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma Trial in Changchun (Rituximab,
Recruiting
- Peripheral T-Cell Lymphoma, Not Otherwise Specified
- Angioimmunoblastic T-cell Lymphoma
- Rituximab
- +4 more
-
Changchun, Jilin, ChinaThe First Bethune Hospital of Jilin University
Apr 7, 2023
Peripheral T-Cell Lymphoma Trial in Zhengzhou (Parsaclisib, Chidamide)
Not yet recruiting
- Peripheral T-Cell Lymphoma
-
Zhengzhou, Henan, ChinaHenan Cancer Hospital/The affiliated Cancer Hospital of ZhengZho
Dec 26, 2021
Relapsed or Refractory Peripheral T-cell Lymphoma Trial in Taiwan (Chidamide)
Not yet recruiting
- Relapsed or Refractory Peripheral T-cell Lymphoma
-
Kaohsiung, Taiwan
- +4 more
Apr 17, 2023
Extranodal NK T Cell Lymphoma, NK-Cell Leukemia Trial in Xuzhou (Anti-CD56 CAR T)
Recruiting
- Extranodal NK T Cell Lymphoma
- NK-Cell Leukemia
- Anti-CD56 CAR T
-
Xuzhou, Jiangsu, ChinaThe Affiliated Hospital of Xuzhou Medical University
Jul 10, 2023
Peripheral T Cell Lymphoma Trial in Beijing (Linperlisib in combined with Chidamide)
Recruiting
- Peripheral T Cell Lymphoma
- Linperlisib in combined with Chidamide
-
Beijing, Beijing/China, China
- +1 more
Oct 9, 2023
Relapsed or Refractory T-cell Lymphomas Trial in Sendai-shi (BMS-986369)
Not yet recruiting
- Relapsed or Refractory T-cell Lymphomas
-
Sendai-shi, Miyagi, JapanLocal Institution - 0001
Sep 12, 2023
Brentuximab Vedotin Intravenous Infusion "Relapsed or Refractory
Active, not recruiting
- Peripheral T Cell Lymphoma
- Pediatric Hodgkin Lymphoma
- Brentuximab Vedotin (Genetical Recombination)
-
Tokyo, JapanTakeda Selected Site
Oct 11, 2022
Peripheral T-cell Lymphoma Trial in Beijing (AK104)
Terminated
- Peripheral T-cell Lymphoma
- AK104
-
Beijing, Beiing, ChinaBeijing Cancer Hospital
Oct 17, 2022
T Cell Lymphoma Trial (Cidapenem combined with azacitidine and mitoxantrone liposome (CAM) regimen)
Not yet recruiting
- T Cell Lymphoma
- Cidapenem combined with azacitidine and mitoxantrone liposome (CAM) regimen
- (no location specified)
Mar 6, 2023
Peripheral T Cell Lymphoma Trial in China (CAR-T Therapy)
Not yet recruiting
- Peripheral T Cell Lymphoma
- CAR-T Therapy
-
Hefei, Anhui, China
- +7 more
Jul 31, 2023
Cutaneous T-Cell Lymphoma, Mature T-cell Malignancies, Peripheral T-Cell Lymphoma Trial run by the NCI (Romidepsin,
Recruiting
- Cutaneous T-Cell Lymphoma
- +3 more
- Romidepsin
- +3 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 23, 2023
Cutaneous T-cell Lymphoma Trial in Beijing (Linperlisib in combined with Chidamide)
Recruiting
- Cutaneous T-cell Lymphoma
- Linperlisib in combined with Chidamide
-
Beijing, Beijing, ChinaPeking Union Medical College Hospital
Sep 8, 2023
Peripheral T-cell Lymphoma Trial in Shanghai (PD-1 antibody+ HDAC inhibitor)
Recruiting
- Peripheral T-cell Lymphoma
- PD-1 antibody+ HDAC inhibitor
-
Shanghai, Shanghai, ChinaDongmei Ji
Dec 3, 2021
Cutaneous T Cell Lymphoma, Fungoides Mycosis Sezary Syndrome Trial in Ann Arbor (Pembrolizumab, Mogamulizumab)
Not yet recruiting
- Cutaneous T Cell Lymphoma
- Fungoides Mycosis Sezary Syndrome
-
Ann Arbor, MichiganUniversity of Michigan Comprehensive Cancer Center
Jul 13, 2023
NK/T Cell Lymphoma, Vascular Immunomother T Cell Lymphoma, Non-Hodgkin Lymphoma Trial in Guangzhou (GNC-038)
Not yet recruiting
- NK/T Cell Lymphoma
- +2 more
-
Guangzhou, Guangdong, China
- +1 more
Jan 12, 2023
Peripheral T/NK Cell Lymphoma (R/R PTCL) Trial (YY-20394)
Recruiting
- Peripheral T/NK Cell Lymphoma (R/R PTCL)
-
Houston, TexasMD Anderson Cancer Center
Oct 19, 2022